H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm’s previously estimated net loss of (62c) per share, the analyst tells investors in a research note. The firm is factoring in greater operating expenses moving forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRIX: